NCR1 and cancer: Moreover, a drug such as nintedanib reduced IL-6 produced by cancer-associated fibroblasts (CAFs), thus enhancing the cytotoxicity of CAR-NK cells against mesothelin-positive cancer by increasing NK cell activating receptors (102).